B

Belite Bio
D

BLTE

80.260
USD
-2.20
(-2.67%)
Market Closed
Volume
2,201
EPS
-1
Div Yield
-
P/E
-73
Market Cap
2,478,375,186
News

Title: Belite Bio

Sector: Healthcare
Industry: Biotechnology
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.